ストックスクリーナーアプリを入手
18.48
1.96%
-0.37
アフターアワーズ：
18.50
0.02
+0.11%
前日終値:
$18.85
開ける：
$18.97
24時間の取引高:
2.09M
Relative Volume:
3.06
時価総額：
$1.01B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+1.54%
1か月 パフォーマンス:
+23.94%
6か月 パフォーマンス:
+59.72%
1年 パフォーマンス:
+2.41%
1日の値動き範囲:
$18.32
$19.58
1週間の範囲:
$18.08
$19.68
52週間の値動き範囲:
$7.80
$19.75
Bicara Therapeutics Inc Stock (BCAX) Company Profile
名前
Bicara Therapeutics Inc
セクター
電話
617-468-4219
住所
116 HUNTINGTON AVENUE SUITE 703, BOSTON
BCAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
18.48 | 1.03B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2025-05-23 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | 開始されました | Wells Fargo | Underweight |
| 2025-02-06 | 開始されました | Wedbush | Outperform |
| 2024-12-06 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-05 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 開始されました | Morgan Stanley | Overweight |
| 2024-10-08 | 開始されました | Stifel | Buy |
| 2024-10-08 | 開始されました | TD Cowen | Buy |
すべてを表示
Bicara Therapeutics Inc (BCAX) 最新ニュース
There is no doubt that Bicara Therapeutics Inc (BCAX) ticks all the boxes. - setenews.com
Promising Efficacy and Investment Potential for Bicara Therapeutics’ FICERA in Combination with Keytruda - TipRanks
Bicara stock maintains Buy rating at Stifel after ESMO-Asia data - Investing.com Nigeria
Bicara stock maintains Buy rating at Stifel after ESMO-Asia data By Investing.com - Investing.com South Africa
Bicara Therapeutics Reports Promising Phase 1b Data - TipRanks
Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Data and Strategic Valuation - TipRanks
Bicara Therapeutics Inc Announces Preliminary Phase 1b Data - TradingView
Bicara Therapeutics reports promising phase 1b data - MSN
Promising Phase 1/1b Results and Future Prospects Boost Bicara Therapeutics’ Buy Rating - TipRanks
Bicara announces preliminary data from Phase 1b cohort of ficerafusp alfa - TipRanks
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026 - GlobeNewswire
Bicara Therapeutics (BCAX): Reassessing Valuation After Breakthrough Therapy Designation and Strong Phase 1b Data - Yahoo Finance
Will Bicara Therapeutics Inc. stock sustain high P E ratios2025 Biggest Moves & Verified Entry Point Detection - Newser
Skandinaviska Enskilda Banken AB publ Acquires 61,201 Shares of Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics (BCAX) Stock Analysis Report | Financials & Insights - Benzinga
Does Bicara Therapeutics Inc (BCAX) offer a good opportunity for investors? - Setenews
Positive Outlook for Bicara Therapeutics: Promising Phase 1b Results and Safety Profile Support Buy Rating - TipRanks
Bicara’s ficerafusp alfa shows consistent response rates at lower dose By Investing.com - Investing.com Australia
Bicara Therapeutics (BCTX) Releases Promising Early Data from Ca - GuruFocus
Bicara’s ficerafusp alfa shows consistent response rates at lower dose - Investing.com
Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025 - GlobeNewswire
Buy Rating for Bicara Therapeutics Driven by Promising Efficacy and Safety of FICERA in ESMO Asia Abstract - TipRanks
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 3.3%Time to Sell? - MarketBeat
Wells Fargo Initiates Coverage of Bicara Therapeutics (BCAX) with Underweight Recommendation - MSN
What Analyst Ratings Reveal About Venus Pipes and Tubes Limiteds Future ValueShort-Term Trading Alerts & Turn Bull Runs into Life-Changing Wealth - earlytimes.in
What’s Bicara Therapeutics Inc (BCAX)’s Price to Earnings Ratio? - fostersleader.com
[424B5] Bicara Therapeutics Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Hyep Ivan, Bicara Therapeutics CFO, sells $341k in BCAX stock - Investing.com Nigeria
Hyep Ivan, Bicara Therapeutics CFO, sells $341k in BCAX stock By Investing.com - Investing.com South Africa
Bicara Therapeutics president Cohlhepp sells $225k in shares By Investing.com - Investing.com South Africa
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity - Stock Titan
Bicara Therapeutics president Cohlhepp sells $225k in shares - Investing.com
Bicara Therapeutics Executives Engage in Stock Sales - TradingView
Pres Cohlhepp Sells 12,500 ($225.6K) Of Bicara Therapeutics Inc [BCAX] - TradingView
Officer Raben Sells 11,000 ($205.1K) Of Bicara Therapeutics Inc [BCAX] - TradingView
Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout (NASDAQ:BCAX) - Seeking Alpha
Ready to Jump After Recent Trade: Bicara Therapeutics Inc (BCAX) - setenews.com
CFO Hyep Files To Sell 605 Of Bicara Therapeutics Inc [BCAX] - TradingView
How Bicara Therapeutics Inc. stock reacts to job market data2025 Price Targets & Safe Entry Momentum Stock Tips - newser.com
Is Bicara Therapeutics Inc. stock safe for conservative investors - newser.com
Why Bicara Therapeutics Inc. stock appeals to analysts2025 Breakouts & Breakdowns & Reliable Momentum Entry Alerts - newser.com
What risks investors should watch in Bicara Therapeutics Inc. stock2025 EndofYear Setup & Consistent Income Trade Recommendations - newser.com
Should I hold or sell Bicara Therapeutics Inc. stock in 2025Insider Buying & Reliable Momentum Entry Alerts - newser.com
What dividend safety score for Bicara Therapeutics Inc. stockWall Street Watch & Long-Term Capital Growth Strategies - newser.com
Bicara Therapeutics Inc (BCAX) 財務データ
Bicara Therapeutics Inc (BCAX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):